ID   DX3-puro/beta6
AC   CVCL_1D33
SY   DX3purobeta6
DR   Wikidata; Q54831609
DR   Ximbio; 151625
RX   PubMed=17699789;
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 6161; ITGB6.
CC   Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Discontinued: Ximbio; 151625; probable.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5650 ! SK-MEL-93 DX-3
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 30-01-24; Version: 11
//
RX   PubMed=17699789; DOI=10.1158/0008-5472.CAN-07-1026;
RA   Hausner S.H., DiCara D., Marik J., Marshall J.F., Sutcliffe J.L.;
RT   "Use of a peptide derived from foot-and-mouth disease virus for the
RT   noninvasive imaging of human cancer: generation and evaluation of
RT   4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin
RT   alphaVbeta6 expression with positron emission tomography.";
RL   Cancer Res. 67:7833-7840(2007).
//